Home > Insider Trading > Filing (0001127602-25-003984)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
318154	Amgen Inc	AMGN	Biological Products, (No Disgnostic Substances) (2836)	953540776

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1365306	P Jonathan Graham	One Amgen Center Drive Thousand Oaks CA 91320-1799	Evp & Gen. Counsel & Secy.	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2025-02-07	25,045	$156.35	54,032	No	4	M	Direct
Common Stock	Disposition	2025-02-07	25,045	$293.12	28,987	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Nqso (Right to Buy)	Disposition	2025-02-07	25,045	$0.00	25,045	$156.35

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0	2018-05-03	2026-05-03	No	4	M	Direct

Footnotes

These shares were acquired in connection with the exercise of stock options expiring on May 3, 2026.
The price reported is an average price. Full information regarding the number of shares sold at each separate price is available upon request by the SEC staff, the issuer or a security holder of the issuer.
These shares include 634 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.